Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (WXIBF)
OTHER OTC:WXIBF
RESEARCH TOOLSreports
Wuxi Biologics (Cayman) (WXIBF) Stock Price & Analysis
118 Followers
WXIBF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $6.60
Previous Close$1.41
Volume4.25K
Average Volume (3M)112.03K
Market Cap
$6.10B
Enterprise Value$5.48B
Total Cash (Recent Filing)¥9.86B
Total Debt (Recent Filing)¥4.40B
Price to Earnings (P/E)12.2
Beta0.80
Next Earnings
Aug 19, 2024EPS Estimate
$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding4,259,278,169
10 Day Avg. Volume122,120
30 Day Avg. Volume112,035
Standard Deviation0.17
R-Squared0.01
Alpha-0.00287
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.75Price Target Upside153.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Shareholders Approve All Resolutions
PremiumCompany Announcements
Wuxi Biologics Awards Restricted Shares to EmployeesPremiumCompany Announcements
WuXi Biologics Announces Upcoming AGM Details
PremiumCompany Announcements
WuXi Biologics Adopts Electronic Communication Updates
Bulls Say, Bears Say
Bulls Say
Market PositionWuXi Bio boasts 13% market share globally and 70% in China.
Revenue GrowthIf excluding COVID revenue, total revenue would increase by 37.7% YoY, and revenue from late-stage and CMO projects would surge by 101.7% YoY.
Share BuybackWuXi Bio has initiated a share repurchase plan with an aggregate value up to US$600mn, demonstrating management's confidence in the business.
Bears Say
Contract TerminationNo new US contracts when the bill is passed, existing US contracts to stop Jan 1st 2032.
EarningsAdj. net profit dropped -5%YOY to RMB 4.7bn, mainly due to investments in new facilities and digital infrastructure.
Regulatory RiskBIOSECURE Act may still get approved, which would restrict the business of WuXi Biologics in US within 6 months of implementation.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
9.74% Mutual Funds
7.04% Other Institutional Investors
83.23% Public Companies and
Individual Investors
WXIBF FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was $1.28 and its highest was $6.60 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Currently, no data Available
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 19, 2024 which is in 28 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 26, 2024. The company reported $0.036 earnings per share for the quarter, missing the consensus estimate of $0.037 by >-$0.001.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is $0.06.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,153,166,000 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of $0.036 in its last earnings report, missing expectations of $0.037. Following the earnings report the stock price went down -2.247%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Among the largest hedge funds holding Wuxi Biologics (Cayman) Inc.’s share is Gilder Gagnon Howe & Co LLC.. It holds Wuxi Biologics (Cayman) Inc.’s shares valued at N/A.
---
Wuxi Biologics (Cayman) Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.75 (153.38% Upside)
$3.75 (153.38% Upside)
Hedge Fund Trend
Decreased
By 8.3M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.80%
12-Months-Change
Fundamentals
Return on Equity
9.01%
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
WXIBF Stock 12 Month Forecast
Average Price Target
$3.75
▲(153.38% Upside)
Technical Analysis
Best Analysts Covering WXIBF
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-44.04%
reiterated a buy rating 2 months ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -44.04% per trade.
---